PFE · Insider Trading
Pfizer Inc.
Every open-market purchase and sale reported by PFE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-16 | Albert Bourla | Chairman & CEO | A | +20 deriv. | — |
| 2026-10-14 | Albert Bourla | Chairman & CEO | A | +71 deriv. | — |
| 2026-10-01 | Albert Bourla | Chairman & CEO | A | +21 deriv. | — |
| 2026-09-29 | Cyrus Taraporevala | Director | A | +1,307 deriv. | — |
| 2026-09-29 | Shantanu Narayen | Director | A | +1,743 deriv. | — |
| 2026-09-29 | James Quincey | Director | A | +1,351 deriv. | — |
| 2026-09-29 | James C Smith | Director | A | +1,569 deriv. | — |
| 2026-09-29 | Mortimer J Buckley | Director | A | +1,307 deriv. | — |
| 2026-09-29 | Joseph Echevarria | Director | A | +1,613 deriv. | — |
| 2026-09-16 | Albert Bourla | Chairman & CEO | A | +22 deriv. | — |
| 2026-09-01 | Albert Bourla | Chairman & CEO | A | +21 deriv. | — |
| 2026-08-17 | Albert Bourla | Chairman & CEO | A | +22 deriv. | — |
| 2026-08-12 | Albert Bourla | Chairman & CEO | Buy | +38,000 | +$1.00M |
| 2026-08-06 | Jennifer B. Damico | SVP & Controller | Sell | −3,278 | −$83.26K |
| 2026-08-06 | Jennifer B. Damico | SVP & Controller | Sell | −3,278 | −$83.26K |
| 2026-08-05 | Ronald E Blaylock | Director | Buy | +39,231 | +$998.82K |
| 2026-08-05 | Mortimer J Buckley | Director | Buy | +37,632 | +$960.37K |
| 2026-08-03 | Albert Bourla | Chairman & CEO | A | +24 deriv. | — |
| 2026-07-16 | Albert Bourla | Chairman & CEO | A | +24 deriv. | — |
| 2026-07-13 | Albert Bourla | Chairman & CEO | A | +84 deriv. | — |
| 2026-07-01 | Albert Bourla | Chairman & CEO | A | +25 deriv. | — |
| 2026-06-16 | Albert Bourla | Chairman & CEO | A | +23 deriv. | — |
| 2026-06-10 | Jennifer B. Damico | SVP & Controller | Sell | −2,000 | −$51.40K |
| 2026-06-01 | Albert Bourla | Chairman & CEO | A | +23 deriv. | — |
| 2026-05-18 | Albert Bourla | Chairman & CEO | A | +24 deriv. | — |
| 2026-05-04 | Albert Bourla | Chairman & CEO | A | +22 deriv. | — |
| 2026-04-27 | Cyrus Taraporevala | Director | A | +7,686 deriv. | — |
| 2026-04-27 | James C Smith | Director | A | +7,686 deriv. | — |
| 2026-04-27 | James Quincey | Director | A | +7,686 deriv. | — |
| 2026-04-27 | Shantanu Narayen | Director | A | +7,686 deriv. | — |
| 2026-04-27 | Joseph Echevarria | Director | A | +7,686 deriv. | — |
| 2026-04-27 | Susan Desmond-Hellmann | Director | A | +7,686 deriv. | — |
| 2026-04-27 | Mortimer J Buckley | Director | A | +7,686 deriv. | — |
| 2026-04-27 | Ronald E Blaylock | Director | A | +7,686 deriv. | — |
| 2026-04-27 | Dan R. Littman | Director | A | +7,686 deriv. | — |
| 2026-04-27 | Johnson Suzanne M Nora | Director | A | +7,686 deriv. | — |
| 2026-04-27 | Scott Gottlieb | Director | A | +7,686 deriv. | — |
| 2026-04-17 | Albert Bourla | Chairman & CEO | A | +22 deriv. | — |
| 2026-04-16 | Albert Bourla | Chairman & CEO | A | +911 deriv. | — |
| 2026-04-01 | Albert Bourla | Chairman & CEO | A | +21 deriv. | — |
| 2026-03-30 | Mortimer J Buckley | Director | A | +1,386 deriv. | — |
| 2026-03-30 | Joseph Echevarria | Director | A | +1,710 deriv. | — |
| 2026-03-30 | Shantanu Narayen | Director | A | +1,849 deriv. | — |
| 2026-03-30 | James Quincey | Director | A | +1,433 deriv. | — |
| 2026-03-30 | James C Smith | Director | A | +1,664 deriv. | — |
| 2026-03-30 | Cyrus Taraporevala | Director | A | +1,386 deriv. | — |
| 2026-03-16 | Albert Bourla | Chairman & CEO | A | +1,630 deriv. | — |
| 2026-03-05 | Alexandre de Germay | Executive Vice President | A | +194,883 deriv. | — |
| 2026-03-05 | Payal Sahni | Executive Vice President | A | +108,268 deriv. | — |
| 2026-03-05 | Michael McDermott | Executive Vice President | A | +151,576 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Albert Bourla | Chairman & CEO | 435,555 | $12.98M |
| Douglas M Lankler | Executive Vice President | 282,071 | $8.40M |
| Sally Susman | Executive Vice President | 251,732 | $7.50M |
| Christoffel Boshoff | President, R&D | 162,088 | $4.83M |
| Rady A Johnson | Executive Vice President | 127,242 | $3.79M |
| Michael McDermott | Executive Vice President | 114,534 | $3.41M |
| Payal Sahni | Executive Vice President | 96,363 | $2.87M |
| Alexandre de Germay | Executive Vice President | 74,377 | $2.22M |
| Ronald E Blaylock | Director | 71,688 | $2.14M |
| Lidia Fonseca | Executive Vice President | 46,455 | $1.38M |
| David M Denton | Chief Financial Officer & EVP | 37,919 | $1.13M |
| Mortimer J Buckley | Director | 37,632 | $1.12M |
| Aamir Malik | Executive Vice President | 29,548 | $880.23K |
| Jennifer B. Damico | SVP & Controller | 28,611 | $852.32K |
| Scott Gottlieb | Director | 10,000 | $297.90K |
| Johnson Suzanne M Nora | Director | 10,000 | $297.90K |
| James C Smith | Director | 3,566 | $106.23K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PFE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.